TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02888301

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo 18F-clofarabine PET/CT

Intervention type: RADIATION
Intervention: Fluorine F 18 Clofarabine
Description: Given IV

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo 18F-clofarabine PET/CT
Study: NCT00289016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
Study: NCT00518362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TW
Description: TW,120 mg/d
Study: NCT04124068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide teeth whitening gel
Description: Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%
Study: NCT01513798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified paleolithic diet and exercise under observation
Description: Modified paleolithic diet and exercise 3 session/week under observation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified paleolithic diet and general advice on exercise
Description: Modified paleolithic diet and general advice on exercise
Study: NCT04018963

Intervention type: PROCEDURE
Intervention: Single nostril approach endoscopic transsphenoidal pituitary surgery
Description: Single nostril approach endoscopic transsphenoidal pituitary surgery

Intervention type: PROCEDURE
Intervention: Bilateral nostril approach endoscopic transsphenoidal pituitary surgery
Description: Bilateral nostril approach endoscopic transsphenoidal pituitary surgery
Study: NCT03173820

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotype guided
Description: Tacrolimus will be prescribed depend on CYP3A5 genotype. CYP3A5\*1/\*1 patients will receive tacrolimus 0.125 mg/kg/day. CYP3A5\*1/\*3 patients will receive tacrolimus 0.1 mg/kg/day. CYP3A5\*3/\*3 patients will received tacrolimus 0.08 mg/kg/day. Tacrolimus target level for this phase will be 5-8 ng/ml.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Conventional
Description: Tacrolimus will be prescribed 0.1 mg/kg /day for all patients to achieve tacrolimus level 5-8 ng/ml.
Study: NCT02710253

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT00860600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: 500mg/vial, iv infusion, 3 \~ 5 times/week, 2.5 \~ 3.5 hr/time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: 500mg/vial, iv infusion, 3 \~ 5 times/week, 2.5 \~ 3.5 hr/time
Study: NCT04194554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: given PO per dose escalation schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 22.5 mg q3 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg daily
Study: NCT03260101

Intervention type: OTHER
Intervention: non intervational
Description: Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
Study: NCT04194554

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: 5-6 fraction SBRT (total dose: 37.5-40 Gy)
Study: NCT03882411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic shared decision making (eSDM) tool
Description: The web application includes depression screening, behavioral activation, and a patient preference driven treatment selection decision aid. Treatment options will include medications, cardiac rehab/exercise program, and therapy. In addition to education, providers will receive a patient preference report in real time with options for coordination of care
Study: NCT04141644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
Study: NCT04124068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide teeth whitening gel
Description: Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide teeth whitening gel
Description: Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLO Brilliant Teeth Whitening Device
Description: Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLO Lit Teeth Whitening Device
Description: Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLO Science Professional Teeth Whitening Device
Description: Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLO Science Professional Teeth Whitening Device
Description: Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
Study: NCT05996757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wet clothing removal
Description: The participants in the intervention group will have their clothing removed prior to insulation.
Study: NCT03795740

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 3-D CT scanning
Description: For patients in Group 1,precisely analyzed CT scanning and/or pulmonary angiography will be done,and the patients in Group 1 will receive PEA procedure with the guide of precise 3-D imaging techniques

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3-D CT scanning
Description: For patients in Group 1,precisely analyzed CT scanning and/or pulmonary angiography will be done,and the patients in Group 1 will receive PEA procedure with the guide of precise 3-D imaging techniques
Study: NCT04141644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
Study: NCT02523027

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (List No S691/Z0)
Description: (List No S691/Z0)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement
Description: (List No- P968/Z0)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counselling
Description: Regular dietary counseling conducted by a trained hospital dietitian.
Study: NCT00968500

Intervention type: BEHAVIORAL
Intervention: Questionnaires/Interviews
Description: Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.~The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer.
Study: NCT02523027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counselling
Description: Regular dietary counseling conducted by a trained hospital dietitian.
Study: NCT02154230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)
Description: During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tap water
Description: During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
Study: NCT03881358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ortho-k lenses and thinner spectacles
Description: Conventinally designed (Emerald) ortho-k lenses (target for -4.00D) and thinner specs during day time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: newly designed ortho-k lenses
Description: Newly designed (Topaz) ortho-k lenses for high myopia (target for full correction)
Study: NCT06356272

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT05876910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Production Tasks
Description: View visual cues and undergo speech production for 30 minutes. Electrical stimulation of speech related brain regions in the middle of speech production.
Study: NCT00727584

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo external beam radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo external beam radiotherapy
Study: NCT04034121

Intervention type: DEVICE
Group type: OTHER
Intervention: DESolve Cx drug eluting coronary scaffold system
Description: percutaneous coronary intervention
Study: NCT02473120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Determination of ESR1 mutations
Description: Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
Study: NCT04056104

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SpO2 and PIx Measurement
Description: Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured
Study: NCT02823496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Lotion , BAY 987521
Description: 50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control
Study: NCT05577780

Intervention type: PROCEDURE
Intervention: internal fixation
Description: Patients with femoral neck fractures are treated with pinning or hip arthroplasty, depending on the age of the patient and the presence and degree of displacement
Study: NCT01396109

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System
Description: Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA\* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
Study: NCT02647242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auto rehabilitation program of gait with Beat Health device.
Description: The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
Study: NCT01396109

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh
Description: Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
Study: NCT01382810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altaire Gel forming solution
Description: Three times a day for two months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Tears
Description: Three times a day for two months
Study: NCT02793609

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention is to let patient to go home.
Description: Intervention is to let patient to go home.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention is to observe women in the ward.
Description: Intervention is to observe women in the ward.
Study: NCT02396056

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: BioMend Extend
Description: Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified BioMend Extend
Description: Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
Study: NCT00543725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: 25 mg tablet once daily for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: 600 mg tablet once daily for 96 weeks
Study: NCT01093196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan, Prednisone, Lenalidomide
Description: Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period \[different doses according to the age of patients (65-75 or \>75 years old);oral Prednisone for 4 days followed by a 24 day rest period.~Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.~ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Prednisone, Lenalidomide
Description: Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period \[day 21 to 28\]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide, dexamethasone
Description: Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
Study: NCT02377531

Intervention type: OTHER
Group type: OTHER
Intervention: Early glucose screen group
Description: Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy

Intervention type: OTHER
Group type: OTHER
Intervention: Standard glucose screen group
Description: Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
Study: NCT02071511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of ventricular arrhythmias
Description: control group: Ablation of ventricular arrhythmias

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ablation of ventricular arrhythmias + renal denervation
Description: Intervention group: Ablation of ventricular arrhythmias + renal denervation
Study: NCT01696565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: Injectable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: Injectable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: Injectable
Study: NCT04379986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senbiosys
Description: The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senbiosys
Description: The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.
Study: NCT01027286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitagel
Description: Vitagel applied just prior to closure during primary total knee arthroplasty
Study: NCT04322656

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lipiflow treatment
Description: Patients will be treated on one eye with Lipiflow
Study: NCT03942822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milled chia seeds
Description: 8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia
Study: NCT04054661

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SD Biosensor STANDARD G6PD Test
Description: The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pointe Scientific Test Kit
Description: The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
Study: NCT01613534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Argon plasma coagulation treatment followed by placebo administration for four weeks
Study: NCT01470937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: acarbose 100 mg PO once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: acarbose placebo
Study: NCT01751893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henna
Description: natural henna in the form of paste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04744792

Intervention type: OTHER
Intervention: Short Form - 36
Description: Medical outcomes: 36-item short form health survey (SF-36)~The SF-36 was used as a measure of health-related QoL because it is an internationally recognized global measure. It comprises 36 items that measure perceived health on eight scales (i.e., physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health) with higher scores (range 0-100) reflecting better perceived health. Additionally, two summary scores can be obtained: the physical component summary score (PCS) and the mental component summary score (MCS).~In addition, this tool has been validated in Turkish patients

Intervention type: OTHER
Intervention: Short Form - 36
Description: Medical outcomes: 36-item short form health survey (SF-36)~The SF-36 was used as a measure of health-related QoL because it is an internationally recognized global measure. It comprises 36 items that measure perceived health on eight scales (i.e., physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health) with higher scores (range 0-100) reflecting better perceived health. Additionally, two summary scores can be obtained: the physical component summary score (PCS) and the mental component summary score (MCS).~In addition, this tool has been validated in Turkish patients
Study: NCT01869829

Intervention type: DRUG
Intervention: Observational antifungal therapy
Description: Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care.
Study: NCT02472548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-RSV(A)
Description: Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
Study: NCT00431288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet high in fruits, vegetables, and dairy

Intervention type: OTHER
Group type: OTHER
Intervention: Routine nutrition care
Study: NCT01790932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study: NCT03027102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNT cells
Description: DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.